Holen Sie sich die Stockscreener-App
169.74
0.73%
1.235
Handel nachbörslich:
170.59
0.85
+0.50%
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
AXSM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Balipodect Licensing Deal From Takeda - Sahm
Element Squared LLC Invests $1.48 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Acquisition Play Signals A Bold Push Into Schizophrenia Market! - Smartkarma
Axsome stock climbs on schizophrenia drug deal with Takeda - MSN
Axsome Acquires Global Rights to TAK-063 from Takeda - Intellectia AI
Piper Sandler Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $223 - Moomoo
Axsome Therapeutics acquires Takeda’s selective PDE10A inhibitor balipodect - The Pharma Letter
AXSM Technical Analysis & Stock Price Forecast - intellectia.ai
Takeda (TAK) Sells Rights to Schizophrenia Drug to Axsome - GuruFocus
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda - Benzinga
Axsome Therapeutics Acquires Global Rights to Balipodect, a Selective PDE10A Inhibitor, for Schizophrenia and Neuropsychiatric Disorders 1 - minichart.com.sg
Axsome acquires global rights to Takeda’s balipodect - TipRanks
Axsome acquires global rights to balipodect from Takeda By Investing.com - Investing.com Canada
Axsome Therapeutics Acquires Exclusive Global Rights to Balipodect from Takeda - MarketScreener
Axsome Therapeutics acquires balipodect, gains global rights and plans Phase 3-enabling work for schizophrenia - TradingView
Axsome acquires global rights to balipodect from Takeda - Investing.com
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions - manilatimes.net
Axsome Therapeutics (NASDAQ: AXSM) secures global rights to balipodect - Stock Titan
Axsome Therapeutics Incto Begin Phase 3 Tr - Moomoo
Axsome Therapeutics (AXSM) Valuation Check After Recent Share Price Cooling - Yahoo Finance
Dow Update: How does Axsome Therapeutics Inc compare to its peersWeekly Trade Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Hennion & Walsh Asset Management Inc. Cuts Stock Position in Axsome Therapeutics, Inc. $AXSM - marketbeat.com
(AXSM) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Why is Axsome (AXSM) down 6.6% since last earnings report? - MSN
Mizuho reiterates Axsome stock Outperform rating on Rx data - Investing.com
Vanguard (AXSM) reports 0 shares after internal realignment - stocktitan.net
Phase 3 trial initiation pushes Axsome Therapeutics stock up amid technical signals of buyer strength - Traders Union
Guggenheim Keeps Their Buy Rating on Axsome Therapeutics (AXSM) - theglobeandmail.com
Axsome Therapeutics (NASDAQ:AXSM) Raised to Strong-Buy at Truist Financial - MarketBeat
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - The Motley Fool
Guggenheim Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - marketbeat.com
Guggenheim raises Axsome stock price target on Alzheimer’s drug outlook - Investing.com
Axsome Therapeutics, Inc. $AXSM Position Increased by Assenagon Asset Management S.A. - MarketBeat
Hypersomnia Pipeline Advances with 3+ Companies Developing Innovative Therapies and Expanding Clinical Research | DelveInsight - Barchart
JPMorgan Chase & Co. Has $30.43 Million Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
AXSM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Market Overview: Is Axsome Therapeutics Inc stock trending bullishTrade Exit Report & Fast Gain Swing Trade Alerts - baoquankhu1.vn
AXSM PE Ratio & Valuation, Is AXSM Overvalued - intellectia.ai
Mizuho reiterates Axsome stock Outperform on Auvelity growth By Investing.com - Investing.com Canada
Analysts Are Bullish on Top Healthcare Stocks: PolyPid (PYPD), Axsome Therapeutics (AXSM) - The Globe and Mail
Axsome Therapeutics’ Q4 numbers beat Wall Street expectations: Analyst sees over 23% upside for stock - MSN
Superstring Capital's New Axsome Therapeutics Position: A $6.84M Biopharma InvestmentNews and Statistics - IndexBox
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain - AOL.com
Wolfe Research initiates coverage of Axsome Therapeutics (AXSM) with outperform recommendation - MSN
Axsome shares slip despite fourth-quarter earnings beat and strong revenue growth - MSN
(AXSM) Risk Channels and Responsive Allocation - Stock Traders Daily
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision - AOL.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Recommendation of "Moderate Buy" from Analysts - marketbeat.com
Axsome Therapeutics, Inc. $AXSM Shares Purchased by Eventide Asset Management LLC - MarketBeat
A Look At Axsome Therapeutics (AXSM) Valuation As Legal Probe And FDA Decision Draw Investor Focus - simplywall.st
Profit Review: How much upside does Axsome Therapeutics Inc have2026 Outlook & Precise Swing Trade Entry Alerts - baoquankhu1.vn
AXSM's 2025 Revenue Growth Primarily Fueled by Auvelity: What Does the Future Hold? - Bitget
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead? - TradingView
RBC Capital reiterates Axsome Therapeutics stock rating at Outperform By Investing.com - Investing.com Canada
Axsome Therapeutics Highlights Auvelity’s $500M+ Run, FDA Catalyst and Late-Stage Pipeline at Conference - MarketBeat
Is It Time To Revisit Axsome Therapeutics (AXSM) After Recent Share Price Weakness - simplywall.st
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):